ArticleNutrition & metabolism2021
The long noncoding RNA MALAT1 modulates adipose loss in cancer-associated cachexia by suppressing adipogenesis through PPAR-γ.
Article in Nutrition & metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- Review
- Tracing of Porcine lncRNAGenes · 2026Article
- Circulating Long Non-Coding RNAs as a Promising Non-Invasive Tool to Trace Adiposity Capacity Following Obesity Surgery.Life (Basel, Switzerland) · 2026Article
- Plasma Circulating lncRNAs: MALAT1 and NEAT1 as Biomarkers of Radiation-Induced Adverse Effects in Laryngeal Cancer Patients.Diagnostics (Basel, Switzerland) · 2025Article
- Hypoglycemia and hyperinsulinemia induced by phenolic uremic toxins in CKD and DKD patients.Scientific reports · 2025Article
- Review
- lncRNA TUG1 transcript levels and psychological disorders: insights into interplay of glycemic index and glycemic load.BMC medical genomics · 2024Article
- Long Non-Coding RNAs, Nuclear Receptors and Their Cross-Talks in Cancer-Implications and Perspectives.Cancers · 2024Review
- Brassinin alleviates cancer cachexia by suppressing diverse inflammatory mechanisms in mice.MedComm · 2024Article
- Extracellular vesicles in cancer cachexia: deciphering pathogenic roles and exploring therapeutic horizons.Journal of translational medicine · 2024Review
- Low expression of ELOVL6 may be involved in fat loss in white adipose tissue of cancer-associated cachexia.Lipids in health and disease · 2024Article
- Review
- Long non-coding RNA (LncRNA) and epigenetic factors: their role in regulating the adipocytes in bovine.Frontiers in genetics · 2024Review
- Construction of predictive ceRNA network and identification of the patterns of immune cells infiltrated in GravesZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023Article
- A single nuclei atlas of aging human abdominal subcutaneous white adipose tissue.Research square · 2023Article
- Review
- Review
- LncRNA-Mediated Adipogenesis in Different Adipocytes.International journal of molecular sciences · 2022Review
- Review
- Identification and analysis of lncRNA, miRNA and mRNA related to subcutaneous and intramuscular fat in Laiwu pigs.Frontiers in endocrinology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundCancer-associated cachexia is a multifactorial syndrome defined by progressive weight loss with ongoing loss of adipose tissue and skeletal muscle. Adipose loss occurs in the early stage of cachexia and is associated with reduced quality of life and survival time. Although numerous lncRNAs are regarded as novel regulators in adipose metabolism, the role of lncRNAs that selectively modulate the development of adipose loss in cachexia remains limited.
methodsIn this study, we analyzed microarray data of lncRNAs in adipose loss and further explored the function and mechanism of MALAT1 in adipose loss. First, we explored the expression and function of MALAT1 in adipose cell by quantitative PCR and RNA knockdown. Subsequently, the mechanism of MALAT1 involvement in adipose loss was analyzed via RNA-seq, bioinformatics analysis and reporter gene assay. Finally, we explored the clinical significance of MALAT1 through correlation analysis.
resultsCellular experiments revealed that knocking down MALAT1 significantly inhibited the process of adipogenesis. RNA-seq data showed that numerous adipogenic genes were downregulated upon MALAT1 knockdown. A protein-protein interaction network analysis identified PPAR-γ as the central node transcription factor, the inhibition of which explains the downregulation of numerous adipogenic genes. A reporter gene assay suggested that MALAT1 can regulate the gene expression of PPAR-γ at the transcriptional level. Moreover, MALAT1 was weakly expressed in the subcutaneous white adipose tissue of cancer-associated cachexia patients and was related to low fat mass index and poor prognosis in cancer patients.
conclusionsThis study indicated that MALAT1 is associated with adipose loss in cancer-associated cachexia by regulating adipogenesis through PPAR-γ, which may potentially be a novel target for the diagnosis and treatment of cancer-associated cachexia in the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.